CLINICAL_TRIALS
trial_result
· 2016-06-15
Clinical Trial Update: Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype [Phase 2]
Summary
Phase 2 trial evaluating cetuximab in refractory colorectal cancer with KRAS mutation and favorable FcγRIIa genotype; results were posted in 2016.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Colorectal Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2016-06-15